Company / SG&A Expense
BIOCRYST PHARMACEUTICALS INC SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$348.6M
FY2025
5-year range
$118.8M / $348.6M
FY2021-FY2025
Trend
+30.9%
vs FY2024
Sector context
#49 of 213
Health Care
What the data says
BIOCRYST PHARMACEUTICALS INC's sg&a expense of $349M is higher than 77% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 9 consecutive years, from $11M in FY2016 to $349M in FY2025.
Based on SEC 10-K filings.
$349M in FY2025 with a 5-year CAGR of +38.7%. Top quartile in the Health Care sector.
Increased from $214M to $349M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +29.8%
- 5-Year CAGR
- +38.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 213This company $348.6M Sector average $722.3M
▼
-51.7% below sector average
Key checks
Key Insights
- BIOCRYST PHARMACEUTICALS INC's sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +38.7%, indicating consistent growth.
- In FY2025, sg&a expense increased 30.9% year-over-year.
- Ranks #49 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $348.6M | +30.9% |
| FY2024 | $266.3M | +24.4% |
| FY2023 | $214.1M | +34.3% |
| FY2022 | $159.4M | +34.1% |
| FY2021 | $118.8M | +74.9% |
| FY2020 | $67.9M | +83.0% |
| FY2019 | $37.1M | +25.8% |
| FY2018 | $29.5M | +111.8% |
| FY2017 | $13.9M | +23.8% |
| FY2016 | $11.3M | -13.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026